阿尔多素向疗法:在耐性高血压和慢性病中早期实施
Masatake Kobayashi1,2, Bertram Pitt3, João Pedro Ferreira1,4
1Université de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France.
European heart journal
|April 11, 2025
概括
耐治疗高血压 (TRH) 和慢性病 (CKD) 与阿尔多素有共同的联系. 对这些复杂的患者来说,阿尔多素向治疗可能会提供超出血压控制的新心脏和脏益处.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐治疗高血压 (TRH) 经常与慢性病 (CKD) 发生,从而增加心血管风险.
- 在TRH和CKD患者中增强的阿尔多和矿物质皮质类受体活性驱动心脏和脏炎症和纤维化.
- 最佳的血压控制和管理与阿尔多相关的风险对于心脏病管理至关重要.
研究的目的:
- 对TRH和CKD患者的阿尔多素向治疗的证据进行审查.
- 重新评估TRH和CKD目前的治疗策略和临床试验设计.
主要方法:
- 审查现有的临床试验数据和关于TRH,CKD和阿尔多斯特的科学文献.
- 分析矿物质皮质体受体抗剂 (MRA) 和新兴疗法的作用.
- 考虑安全性概况,特别是慢性病患者的高血症风险.
主要成果:
- 矿物质皮质类受体抗剂 (MRA) 建议用于TRH,但高胆固醇血的风险限制了它们在CKD中的使用.
- 非类固醇MRA和SGLT2抑制剂显示出心脏和脏的好处,并减缓脏衰退.
- 阿尔多氨酸合成酶抑制剂代表了TRH的潜在未来治疗途径.
结论:
- 仅仅降低血压可能不足以防止TRH和CKD中心脏病的进展.
- 以阿尔多素为向的疗法对改善这一患者群体的心脏病结局具有显著的前景.
- 未来的临床试验应将阿尔多素阻断作为主要或次要终点.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
01:25Antihypertensive Drugs: Direct Renin Inhibitors
447
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
447
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
410
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
410
01:33Hormonal Regulation
32.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
01:22Heart Failure Drugs: Diuretics
295
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
295
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
544
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
544